GSK's lapatinib fails in Phase III gastric cancer trial
This article was originally published in Scrip
Executive Summary
A Phase III trial of GlaxoSmithKline's lapatinib (Tykerb/Tyverb) in combination with chemotherapy in patients with HER2-positive advanced gastric cancer has failed.